Comparison of Epiduo Associated With Lymecycline Versus Epiduo Vehicle Associated With Lymecycline in Acne Vulgaris (TEAM)
Efficacy and Safety Comparison of Epiduo Gel Associated With Lymecycline 300 mg Capsules Versus Epiduo Vehicle Gel Associated With Lymecycline 300 mg Capsules in the Treatment of Moderate to Severe Acne Vulgaris
Sponsor: Galderma R&D
Listed as NCT01014689, this PHASE3 trial focuses on Acne Vulgaris and remains completed. Sponsored by Galderma R&D, it has been updated 8 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Aug 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Galderma R&D
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Belo Horizonte, Brazil , Bordeaux, France , Brussels, Belgium , Canberra, Australia , Cannes, France , Catania, Italy , Cuxhaven, Germany , Darmstadt, Germany , Eskilstuna, Sweden , Farsta, Sweden and 18 more locations